- Abstract Number: 1819 • 2015 ACR/ARHP Annual Meeting - Comparison of Electrocardiographic ST-T Changes and QTc Duration in Patients with Systemic Lupus Erythematosus and Rheumatoid ArthritisBackground/Purpose: Cardiovascular disease (CVD) is a leading cause of death in systemic lupus erythematosus (SLE) and in rheumatoid arthritis (RA). Longer corrected QT segments (QTc)…
- Abstract Number: 1820 • 2015 ACR/ARHP Annual Meeting - Prevalence and Risk-Factors for Asymptomatic Coronary-Artery Calcifications in Young Patients with Systemic Lupus ErythematosusBackground/Purpose: Premature atherosclerosis is a major cause of morbidity and mortality in females with systemic lupus erythematosus (SLE), but little is known about the frequency,…
- Abstract Number: 1821 • 2015 ACR/ARHP Annual Meeting - Leptin, Adiponectin, and Resistin As Serum Markers of Fatigue in Systemic Lupus Erythematosus: A Pilot StudyBackground/Purpose: Fatigue, a common symptom in systemic lupus erythematosus (SLE) patients, is ameliorated by physical activity. Adiposity and adipokines may be associated with patient-reported fatigue.…
- Abstract Number: 1822 • 2015 ACR/ARHP Annual Meeting - Pharmacokinetics of the Selective B-Cell Lymphoma-2 (Bcl-2) Inhibitor, ABT-199, in Female Subjects with Systemic Lupus ErythromatosusBackground/Purpose: Selective Inhibition of Bcl-2 pathway may offer clinical efficacy in Systemic Lupus Erythromatosus (SLE) by restoring apoptosis in autoreactive cells, which may lead to…
- Abstract Number: 1823 • 2015 ACR/ARHP Annual Meeting - Visceral Adiposity in Premenopausal Lupus Patients: Correlation with Systemic InflammationBackground/Purpose: SLE is associated with high prevalence of metabolic syndrome and obesity, which can be related to the high risk of cardiovascular events in this…
- Abstract Number: 1824 • 2015 ACR/ARHP Annual Meeting - Tripterygium Wilfordii for the Treatment of Systemic Lupus Systematosus: Meta-Analysis of Randomized Controlled TrialsBackground/Purpose: Tripterygium Wilfordii (TPW), a Chinese herbal medication, has been widely used in China for various chronic inflammatory and autoimmune diseases, including systemic lupus erythematosus…
- Abstract Number: 1825 • 2015 ACR/ARHP Annual Meeting - Osteoprotegerin Is Associated with Lupus and with Coronary Artery CalcificationBackground/Purpose: In the general population, we and others have reported that higher osteoprotegerin (OPG), a protein involved in bone remodeling, is associated with higher levels…
- Abstract Number: 1826 • 2015 ACR/ARHP Annual Meeting - Small LDL-P Increases with Increased Disease Activity in SLEBackground/Purpose: Systemic lupus erythematosus (SLE) associates with accelerated atherosclerotic cardiovascular (CV) disease which is not fully explained by traditional CV risk factors. Disease activity, prednisone…
- Abstract Number: 1827 • 2015 ACR/ARHP Annual Meeting - Plasma Myeloperoxidase Levels Are Inversely Associated with Carotid Plaque in SLEBackground/Purpose: : Women with SLE have increased risk of atherosclerosis (ATH) that is not adequately explained by traditional risk factors. We previously discovered that a…
- Abstract Number: 1828 • 2015 ACR/ARHP Annual Meeting - Target Modulation of a Type I Interferon Gene Signature and Pharmacokinetics of Anifrolumab in a Phase IIb Study of Patients with Moderate to Severe Systemic Lupus ErythematosusBackground/Purpose: Anifrolumab is a fully human IgG1 monoclonal antibody directed against subunit 1 of the type I interferon receptor (IFNAR1). Anifrolumab blocks the binding of…
- Abstract Number: 1829 • 2015 ACR/ARHP Annual Meeting - Heart Rate Variability Is Associated with SLE Flare and with TNF- and IFN-Mediated SignalingBackground/Purpose: Decreased heart rate variability (HRV), associated with adverse outcomes in cardiovascular diseases, is frequently seen in patients with SLE. The LF/HF ratio, a HRV…
- Abstract Number: 1830 • 2015 ACR/ARHP Annual Meeting - Periodontal Disease in Lupus Erythematosus and Cardiovascular Risk FactorsBackground/Purpose: The aim of this study was to determine the prevalence of periodontal disease (POD) in patients with Systemic Lupus Erythematosus (SLE) and its relationship with…
- Abstract Number: 1831 • 2015 ACR/ARHP Annual Meeting - Initial Risk Factor Profile and Long-Term Cardiovascular Outcome in Women with Systemic Lupus ErythematosusBackground/Purpose: We previously reported the influence of traditional and disease-related risk factors on the development of cardiovascular disease (CVD) in patients with systemic lupus erythematosus…
- Abstract Number: 1832 • 2015 ACR/ARHP Annual Meeting - Recurrence-Rate of Thrombotic Events in SLE Patients Negative for Antiphospholipid AntibodiesBackground/Purpose: Thrombotic events (TE) are common in patients with SLE. Antiphospholipid antibodies (aPL) are a risk factor for incident and recurrent TE; therefore these patients…
- Abstract Number: 1833 • 2015 ACR/ARHP Annual Meeting - Musculoskeletal Complications of Systemic Lupus Erythematosus: Risk Factors for and Prevalence of Avascular Necrosis and OsteoporosisBackground/Purpose: Osteoporosis (OP) and avascular necrosis (AVN) are well-recognized musculoskeletal complications of systemic lupus erythematosus (SLE) and cause morbidity. Steroid therapy and the underlying disease…
